Utah Medical Products, Inc. (UTMD) Stock Score, Valuation & Financial Research
Utah Medical Products, Inc. is in the Healthcare sector and Medical - Instruments & Supplies industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 45/100.
Quick answer for UTMD
Utah Medical Products, Inc. currently has a Wall Street Score of 45/100. The stored market price is $74.63. Its financial score is 60/100. Its valuation score is 16/100. These figures are a research snapshot, not a buy or sell recommendation.
What Utah Medical Products, Inc. does
Utah Medical Products, Inc. (UTMD) is a healthcare technology company focused on the creation, production, and supply of medical devices for the healthcare sector. UTMD offers a comprehensive portfolio of medical devices primarily serving labor and delivery departments and neonatal intensive care units. Key offerings include fetal monitoring accessories, vacuum-assisted delivery systems, and other specialized tools for childbirth. For newborns, they provide respiratory hoods (DISPOSA-HOOD), umbilical vessel catheters (GESCO), silicone oral protection devices (PALA-NATE), and lumbar sampling kits (MYELO-NATE). Beyond maternity care, the company supplies blood pressure monitoring systems (DELTRAN PLUS), disposable peritoneal dialysis sets (DIALY-NATE), urinary drainage systems (URI-CATH), and feeding devices (NUTRI-CATH/NUTRI-LOK). They also manufacture HEMO-NATE disposable filters, variou
UTMD financial snapshot
- Wall Street Score:
- 45/100
- Current price:
- $74.63
- Market capitalization:
- $237.6M
- Revenue:
- $37.5M
- Net income:
- $10.8M
- Free cash flow:
- $14.3M
- Cash:
- $87.4M
- Total debt:
- $210K
- EPS:
- 3.41
- P/E ratio:
- 21.9x
- Financial score:
- 60/100
- Valuation score:
- 16/100
- Revenue score:
- 19/100
What stands out
- Reported year-over-year revenue growth is -0.0%.
- Free cash flow is $14.3M, showing positive cash generation.
- The balance sheet shows $87.4M of cash versus $210K of total debt, leaving more cash than debt.
What the numbers mean
Its current valuation score is 16/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 60/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research UTMD
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.